Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $313 from $303 and keeps a Buy rating on the shares. The firm sees a “clear path” to a new drug application filing for relutrigine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Plans New Drug Application
- Praxis Precision achieves alignment on elsunersen pathway following FDA meeting
- Praxis Precision price target raised to $450 from $300 at Jefferies
- Praxis Precision Medicines: Promising Epilepsy Portfolio Advances Justify Buy Rating
- Praxis Precision price target raised to $760 from $540 at Guggenheim